This phase II trial is trying to find out how effective it is to treat patients, diagnosed with T-Cell Prolymphocytic Leukemia, with a targeted therapy (Ibrutinib) in combination with chemotherapy (Venetoclax)A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia

Inclusion

• Adequate liver, kidney and hematology function per laboratory values as described in the protocol.
• Diagnosis of T-cell prolymphocytic leukemia (T-PLL) that requires treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
• Received prior alemtuzumab (unless unsuitable or unavailable).

• Has no malignancies other than T-PLL that:

  • currently require systemic therapies;
  • were not previously treated with curative intention (unless the malignant disease is in a stable remission due to the discretion of the treating physician); or
  • developed signs of progression after curative treatment.